Richard Ross

USPTO Granted Patents = 17 (Patent Applications = 15)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 21(Granted Patents)

Company Filing History:

University of Sheffield

patents

Years Active: 2008-2022

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11344606 - Parathyroid hormone fusion polypeptide (2022-05-31),

2. 10166194 - Hydrocortisone controlled release formulation (2019-01-01),

3. 10030062 - Growth hormone fusion proteins with growth hormone receptor agonist activity (2018-07-24),

4. 9750704 - Hydrocortisone controlled release formulation (2017-09-05),

5. 9717740 - Treatment of adrenal insufficiency (2017-08-01),

6. 9675559 - Treatment of adrenal insufficiency (2017-06-13),

7. 9649280 - Composition comprising hydrocortisone (2017-05-16),

8. 9493536 - Growth hormone receptor antagonists (2016-11-15),

9. 9012436 - Lipid composition (2015-04-21),

10. 8470559 - Growth hormone fusion proteins (2013-06-25),

11. 8293709 - Growth hormone fusion proteins (2012-10-23),

12. 8273552 - Modified growth hormone polypeptides (2012-09-25),

13. 8173782 - Fusion protein comprising growth hormone and growth hormone receptor (2012-05-08),

14. 7625998 - Cytokine polypeptides and antibodies containing a signal sequence for the attachment of glycosylphosphatidylinositol (2009-12-01),

15. 7524649 - Modified growth hormone fusion polypeptides (2009-04-28),

Title: Richard Ross: Innovator in Pharmaceutical Science

Introduction

Richard Ross is a prominent inventor based in Sheffield, GB. He has made significant contributions to the field of pharmaceutical science, holding a total of 17 patents. His work primarily focuses on innovative treatments for various medical conditions.

Latest Patents

Among his latest patents is the development of a parathyroid hormone fusion polypeptide. This invention relates to long-acting parathyroid or parathyroid hormone-like fusion polypeptides, which comprise a receptor polypeptide. It is particularly useful in the treatment of hypoparathyroidism and osteoporosis. Another notable patent is a hydrocortisone controlled release formulation. This pharmaceutical formulation includes hydrocortisone and is designed for conditions that would benefit from a delayed release, such as adrenal insufficiency, inflammatory conditions, and depression.

Career Highlights

Richard has worked with several companies throughout his career, including Asterion, Inc. and Diurnal Limited. His expertise in pharmaceutical formulations has positioned him as a key player in the industry.

Collaborations

Some of his notable coworkers include Peter Artymiuk and Jon Sayers. Their collaborative efforts have contributed to the advancement of innovative treatments in the pharmaceutical sector.

Conclusion

Richard Ross is a distinguished inventor whose work has significantly impacted the field of pharmaceutical science. His innovative patents and collaborations continue to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.